Have a feature idea you'd love to see implemented?
Let us know!
PRME Prime Medicine Inc
Price (delayed)
$2.97
Market cap
$389.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.06
Enterprise value
$298.76M
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime
Highlights
PRME's revenue is up by 35% QoQ
PRME's gross profit is up by 35% from the previous quarter
The EPS has plunged by 178% YoY but it has grown by 5% from the previous quarter
The quick ratio has increased by 42% YoY but it has decreased by 24% from the previous quarter
PRME's debt has surged by 142% year-on-year
PRME's net income is down by 28% year-on-year
Key stats
What are the main financial stats of PRME
Market
Valuations
Earnings
Shares outstanding
131.16M
Market cap
$389.55M
Enterprise value
$298.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.88
Price to sales (P/S)
444.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
373.45
Revenue
$800,000
EBIT
-$219.25M
EBITDA
-$200.1M
Free cash flow
-$190.32M
Per share
Balance sheet
Liquidity
EPS
-$2.06
Free cash flow per share
-$1.59
Book value per share
$1.58
Revenue per share
$0.01
TBVPS
$2.78
Total assets
$332.78M
Total liabilities
$143.28M
Debt
$41.25M
Equity
$189.5M
Working capital
$208.19M
Debt to equity
0.22
Current ratio
6.5
Quick ratio
6.46
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-25,012%
Gross margin
100%
Net margin
-27,406.1%
Operating margin
-28,286%
Return on assets
-79.9%
Return on equity
-115%
Return on invested capital
-119.4%
Return on capital employed
-74.3%
Return on sales
-27,406.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRME stock price
How has the Prime Medicine stock price performed over time
Intraday
-0.67%
1 week
-17.39%
1 month
-32.04%
1 year
-56.58%
YTD
-66.48%
QTD
-23.26%
Financial performance
How have Prime Medicine's revenue and profit performed over time
Revenue
$800,000
Gross profit
$800,000
Operating income
-$226.29M
Net income
-$219.25M
Gross margin
100%
Net margin
-27,406.1%
PRME's revenue is up by 35% QoQ
PRME's gross profit is up by 35% from the previous quarter
The operating income has contracted by 29% YoY
PRME's net income is down by 28% year-on-year
Growth
What is Prime Medicine's growth rate over time
Valuation
What is Prime Medicine stock price valuation
P/E
N/A
P/B
1.88
P/S
444.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
373.45
The EPS has plunged by 178% YoY but it has grown by 5% from the previous quarter
PRME's price to book (P/B) is 52% lower than its last 4 quarters average of 3.9
Prime Medicine's equity has decreased by 3.6% from the previous quarter and by 2.3% YoY
PRME's revenue is up by 35% QoQ
Efficiency
How efficient is Prime Medicine business performance
The return on equity has dropped by 71% year-on-year
Prime Medicine's return on assets has decreased by 38% YoY but it has increased by 8% QoQ
The ROS has grown by 26% from the previous quarter
The return on invested capital has declined by 10% year-on-year but it has grown by 5% since the previous quarter
Dividends
What is PRME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRME.
Financial health
How did Prime Medicine financials performed over time
PRME's total assets is 132% greater than its total liabilities
The total liabilities has surged by 127% since the previous quarter
The quick ratio has increased by 42% YoY but it has decreased by 24% from the previous quarter
PRME's debt is 78% smaller than its equity
Prime Medicine's debt to equity has surged by 144% YoY and by 4.8% QoQ
PRME's debt has surged by 142% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.